Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

TitlePhosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Publication TypeJournal Article
Year of Publication2010
AuthorsBarone, I, Iacopetta, D, Covington, KR, Cui, Y, Tsimelzon, A, Beyer, A, Andò, S, Fuqua, SAW
Date Published2010 Apr 22
KeywordsAromatase Inhibitors, Breast Neoplasms, Cell Line, Tumor, Drug Resistance, Neoplasm, Estrogen Receptor alpha, Female, Humans, Insulin Receptor Substrate Proteins, Mutation, Phosphorylation, Proto-Oncogene Proteins c-akt, Receptor Cross-Talk, Receptor, IGF Type 1, Serine

We earlier identified a lysine to arginine transition at residue 303 (K303R) in estrogen receptor alpha (ERalpha) in invasive breast cancers, which confers resistance to the aromatase inhibitor (AI) anastrozole (Ana) when expressed in MCF-7 breast cancer cells. Here, we show that AI resistance arises through an enhanced cross talk of the insulin-like growth factor receptor-1 (IGF-1R)/insulin receptor substrate (IRS)-1/Akt pathway with ERalpha, and the serine (S) residue 305 adjacent to the K303R mutation has a key function in mediating this cross talk. The ERalpha S305 residue is an important site that modifies response to tamoxifen; thus, we questioned whether this site could also influence AI response. We generated stable transfectants-expressing wild-type, K303R ERalpha or a double K303R/S305A mutant receptor, and found that the AI-resistant phenotype associated with expression of the K303R mutation was dependent on activation of S305 within the receptor. Ana significantly reduced growth in K303R/S305A-expressing cells. Preventing S305 phosphorylation with a blocking peptide inhibited IGF-1R/IRS-1/Akt activation and also restored AI sensitivity. Our data suggest that the K303R mutation and the S305 ERalpha residue may be a novel determinant of AI response in breast cancer, and blockade of S305 phosphorylation represents a new therapeutic strategy for treating tumors resistant to hormone therapy.

Alternate JournalOncogene
PubMed ID20101208
PubMed Central IDPMC2922934
Grant ListR01 CA072038 / CA / NCI NIH HHS / United States
R01 CA072038-12 / CA / NCI NIH HHS / United States
R01 CA72038 / CA / NCI NIH HHS / United States